Search for: "David M. Lowe " Results 1 - 20 of 1,695
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
30 May 2024, 12:28 pm by Jeffrey Randa
It’s hard to accurately total up these additional costs, but it’s realistic to estimate anywhere from $7000 on the low end to as much as $15,000 on the high end. [read post]
26 May 2024, 7:30 am by David Bernstein
The most antisemitic are the extreme left, the extreme right, as one of the theories noted above suggests, but also low information voters, who skew survey results by often self-identifying as "moderate. [read post]
17 May 2024, 3:03 pm by Yosi Yahoudai
David Garcelon, president of the Institute for Wildlife Studies, believes the risk is worth it. [read post]
13 May 2024, 5:01 am by Eugene Volokh
Constitution, even when pertaining to so-called "low-value" speech forms. [read post]
3 May 2024, 8:49 am by Eugene Volokh
(I'm quite skeptical of the view that official international recognition should make a difference for which arguments are legitimate, and especially for which arguments are protected by the First Amendment.) [read post]
22 Apr 2024, 5:29 am by Beatrice Yahia
David Cohen and Paul Rozenheimer report for POLITICO. [read post]
13 Apr 2024, 3:33 pm by admin
Prelude to Litigation Phenylpropanolamine (PPA) was a widely used direct α-adrenergic agonist used as a medication to control cold symptoms and to suppress appetite for weight loss.[1] In 1972, an over-the-counter (OTC) Advisory Review Panel considered the safety and efficacy of PPA-containing nasal decongestant medications, leading, in 1976, to a recommendation that the agency label these medications as “generally recognized as safe and effective. [read post]
12 Apr 2024, 6:30 am
Adams, Skadden, Arps, Slate, Meagher & Flom LLP, on Sunday, April 7, 2024 Tags: disclosures, EDGAR, Proxy Card, Proxy season, proxy statements, SEC Not at Any Price – Contested M&A, The New Normal Posted by Riyaz Lalani and Dan Gagnier, Gagnier Communications, on Monday, April 8, 2024 Tags: boards, Institutional Shareholders, M&A, Public Companies, Shareholders The Neoclassical View of Corporate Fiduciary Duty Law Posted by Zachary J. [read post]
12 Apr 2024, 6:30 am
Adams, Skadden, Arps, Slate, Meagher & Flom LLP, on Sunday, April 7, 2024 Tags: disclosures, EDGAR, Proxy Card, Proxy season, proxy statements, SEC Not at Any Price – Contested M&A, The New Normal Posted by Riyaz Lalani and Dan Gagnier, Gagnier Communications, on Monday, April 8, 2024 Tags: boards, Institutional Shareholders, M&A, Public Companies, Shareholders The Neoclassical View of Corporate Fiduciary Duty Law Posted by Zachary J. [read post]
7 Apr 2024, 8:26 am
"Writes Gary Shteyngart, in "Crying Myself to Sleep on the Biggest Cruise Ship Ever/Seven agonizing nights aboard the Icon of the Seas" (The Atlantic).Shteyngart is well aware that David Foster Wallace already wrote “A Supposedly Fun Thing I’ll Never Do Again” — AKA "Shipping Out" — and much as I'd rather read a Gary Shteyngart novel than a David Foster Wallace novel, he has no hope of besting Wallace in what, after… [read post]
4 Apr 2024, 4:00 am by Administrator
In Canada, there is a low threshold for what constitutes a defamatory statement: as long as a communication “would cause the plaintiff to lose respect or esteem in the eyes of others,” that communication can be cause for a defamation lawsuit. [read post]
3 Apr 2024, 12:34 pm by David Reiss
President and Joseph Crea Dean David D. [read post]